Comparative effectiveness of low‐level laser therapy with different wavelengths and transcutaneous electric nerve stimulation in the treatment of pain caused by temporomandibular disorders: A systematic review and network meta‐analysis

  • Hui Ren
    Department of Temporomandibular joint and Occlusion School/Hospital of Stomatology Lanzhou University Lanzhou China
  • Jingying Liu
    Department of Temporomandibular joint and Occlusion School/Hospital of Stomatology Lanzhou University Lanzhou China
  • Yang Liu
    Department of Temporomandibular joint and Occlusion School/Hospital of Stomatology Lanzhou University Lanzhou China
  • Caiyun Yu
    Department of Temporomandibular joint and Occlusion School/Hospital of Stomatology Lanzhou University Lanzhou China
  • Guangjie Bao
    Key Laboratory of Stomatology of State Ethnic Affairs Commission Northwest Minzu University Lanzhou China
  • Hong Kang
    Department of Temporomandibular joint and Occlusion School/Hospital of Stomatology Lanzhou University Lanzhou China

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>To assess the efficacy of low‐level laser therapy (LLLT) with different wavelengths and transcutaneous electric nerve stimulation (TENS) and explore the optimal wavelength range of laser application in the treatment of pain caused by temporomandibular disorders (TMD).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>An electronic search on PubMed, Cochrane Library, Embase, Scopus and Web of Science was undertaken to identify the randomised clinical trials (RCTs) published from database inception to 16 April 2021, aiming to compare the effects of LLLT with different wavelengths (632.8–672 nm, 780–904 nm, and 910–1100 nm) or TENS or placebo group on TMD patients pain reduction. In addition, manual search of the studies was performed. The reviewers assessed the risk of bias of individual studies with the Cochrane risk of bias tool and excluded the RCTs with a high risk of bias in any field. Meanwhile, the reviewers, after performing the network meta‐analysis, assessed the quality of evidence, which contributed to network estimate via the GRADE framework.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Twenty‐seven RCTs with 969 patients with TMD were included. In the meta‐analysis, all treatment groups showed an overall improvement in pain scores, when compared with the placebo group. LLLT with wavelength ranging from 910 nm to 1100 nm produced more pain relief in the visual analogue scale (VAS) immediately after treatment [mean difference (MD) = 4.68, 95% confidence interval (CI):(3.08,6.28)]. After one‐month follow‐up, LLLT with wavelength ranging from 910 nm to 1100 nm also showed superior pain‐relieving effects [MD = 3.61, 95% CI: (−1.77, 8.99)]. However, no significant difference was observed. Based on the SUCRA ranking, L3 ranked first immediately after treatment and 1 month later.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The results of the meta‐analysis showed the LLLT had better short‐term efficacy than TENS in the treatment of pain caused by TMD. Better results can be achieved with higher wavelengths. Therefore, we recommended to treat TMD using LLLT with wavelength ranging from 910 nm to 1100 nm.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ